Elena V. Glazkova
Elena V. Glazkova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- A.A. Giatsintova
Blokhin National Medical Research Center of Oncology
1 shared publication - Alexey A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
1 shared publication - Arina A. Datsiuk
ГАУЗ НО "НИИКО "НОКОД
1 shared publication - Denis Sergeevich Fedorinov
Federal State Budgetary Research Institution «Russian Research Center of Surgery Named After Academician B.V. Petrovsky», Moscow 119991, Russia
1 shared publication - E. V. Golovanova
Russian University of Medicine
1 shared publication - Egor P. Fekhtel
Moscow State Budgetary Healthcare Institution "Moscow City Hospital named after S.S. Yudin, Moscow Healthcare Department
1 shared publication
Latest Publications
- Open Access
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Comparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- 8 April 2026
- Published by Consilium Medicum in Journal of Modern Oncology
- Vol. 28 (1) , 37-45
Open AccessComparison of the efficacy of regorafenib and reintroduction of a combination of chemotherapy with anti-EGFR antibody in the third-line treatment of metastatic colorectal cancer with wild-type RAS and BRAF genes of left-sided localization – Results of a multicenter study of real-world practice
Aim. To compare the efficacy and toxicity of regorafenib therapy and the repeated use of anti-EGFR monoclonal antibodies (mAb) combined with chemotherapy (CT) in the third-line treatment of patients with left-sided metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF genes who received anti-EGFR targeted therapy in the first line of treatment. Materials and methods. The database of patients with mCRC from 5 clinics in the Russian Federation was retrospectively analyzed. The study had 3 arms depending on the third-line therapy: regorafenib, reintroduction and rechallenge with the combination of CT and anti-EGFR mAb. In this paper, we present data comparing reintroduction and regorafenib therapy. Results. 132 patients with morphologically confirmed left-sided mCRC with wild-type RAS and BRAF genes who received at least 3 lines of drug therapy from 2014 to 2023 were identified: the first-line therapy included anti-EGFR mAb; 61 patients were reintroduced with a combination of CT with anti-EGFR mAb, and 71 patients received regorafenib in the third-line therapy. Disease control in the reintroduction group was achieved in 43 (70.5%) patients, compared with 18 (25.5%) in the regorafenib group (p = 0.0001). The six-month overall survival (OS) was 76% in the reintroduction group and 55% in the regorafenib group. The median OS in the reintroduction group was 18 months (95% confidence interval [CI] 11.9-24.0 months) and 10 months in the regorafenib group (95% CI 5.3-14.6 months; p = 0.05 according to the log-rank test; p = 0.013 according to the Breslow-Wilcoxon test; p = 0.024 according to the Tarone-Ware test; risk ratio 1.1, 95% CI 0.886-1.408; p = 0.349). Progression-free survival (PFS) was higher in the CT reintroduction group with anti-EGFR mAb (6 months [95% CI 5.3-6.6 months] than in the regorafenib group (3 months [95% CI 2.2-3.7 months]; p = 0.0001 according to the log-rank test, risk ratio 1.23, 95% CI 0.997-1.529; p = 0.053). We found no difference in the incidence of all-grade adverse events between the study groups (p = 0.19), nor in the incidence of grade 3-4 adverse events (p = 0.781). Conclusion. Compared with regorafenib therapy, re-administration of a combination of CT with anti-EGFR targeted therapy in the third-line treatment of patients with left-sided mCRC with wild-type RAS and BRAF genes was associated with a higher rate of disease control and better PFS and 6-month OS.
- 29 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (6) , 78-87
Chemotherapy-associated clinical dynamics of nosogenic reactions in breast and ovarian cancer model
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение особенностей клинической картины, динамики и факторов развития нозогенных реакций у пациенток с онкологическими заболеваниями молочной железы и яичников на этапе химиотерапии. МАТЕРИАЛ И МЕТОДЫ В исследовании приняли участие 35 пациенток, которые проходили химиотерапевтическое лечение. Для оценки психического состояния использовались клинико-психопатологический и психометрический методы. РЕЗУЛЬТАТЫ Выделены 3 типа нозогений: тревожно-фобическая (n=14, 40%), тревожно-депрессивная (n=13, 37%) и диссоциативная реакции (n=8, 23%). Выявлено, что нозогенные реакции отражают связанную с химиотерапией динамику психопатологических расстройств и сопряжены с преморбидной структурой личности пациента. При сравнении по шкалам СМОЛ различия были выявлены между пациентками тревожно-фобической и диссоциативной групп: показатель по шкале «Тревога и депрессивные тенденции» был значимо выше в группе пациенток с тревожно-фобической нозогенной реакцией (pp<0,05). По результатам шкалы тревоги Спилбергера—Ханина, в целом для выборки был характерен повышенный уровень тревожности по сравнению с нормой: средний показатель по субшкале личностной тревожности составил 49,7 балла, по субшкале ситуативной тревожности — 47,7 балла. ЗАКЛЮЧЕНИЕ Нозогенные реакции могут претерпевать динамическое изменение на различных этапах лечения. Предложенная типология нозогений при более подробном изучении может иметь не только научное, но и практическое значение для определения персонализированной тактики психиатрической помощи онкологическим пациентам на разных этапах болезни.
- 29 June 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (6) , 78-87
Chemotherapy-associated clinical dynamics of nosogenic reactions in breast and ovarian cancer model
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение особенностей клинической картины, динамики и факторов развития нозогенных реакций у пациенток с онкологическими заболеваниями молочной железы и яичников на этапе химиотерапии. МАТЕРИАЛ И МЕТОДЫ В исследовании приняли участие 35 пациенток, которые проходили химиотерапевтическое лечение. Для оценки психического состояния использовались клинико-психопатологический и психометрический методы. РЕЗУЛЬТАТЫ Выделены 3 типа нозогений: тревожно-фобическая (n=14, 40%), тревожно-депрессивная (n=13, 37%) и диссоциативная реакции (n=8, 23%). Выявлено, что нозогенные реакции отражают связанную с химиотерапией динамику психопатологических расстройств и сопряжены с преморбидной структурой личности пациента. При сравнении по шкалам СМОЛ различия были выявлены между пациентками тревожно-фобической и диссоциативной групп: показатель по шкале «Тревога и депрессивные тенденции» был значимо выше в группе пациенток с тревожно-фобической нозогенной реакцией (pp<0,05). По результатам шкалы тревоги Спилбергера—Ханина, в целом для выборки был характерен повышенный уровень тревожности по сравнению с нормой: средний показатель по субшкале личностной тревожности составил 49,7 балла, по субшкале ситуативной тревожности — 47,7 балла. ЗАКЛЮЧЕНИЕ Нозогенные реакции могут претерпевать динамическое изменение на различных этапах лечения. Предложенная типология нозогений при более подробном изучении может иметь не только научное, но и практическое значение для определения персонализированной тактики психиатрической помощи онкологическим пациентам на разных этапах болезни.
- Open Access
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 148-153-153
Clinical case of the use of oral metronomic vinorelbin in patient with metastatic Her2 negative breast cancer
Endocrine therapy in combination with inhibitors of cyclin-dependent kinases 4/6 in first lines is the current standard of treatment of metastatic ER positive Her2 negative breast cancer. After progression on several lines of endocrine therapy according to current principles we apply sequential lines of monochemotherapy. If possible non-toxic agents are prefered in order to maintain high quality of life. The special role in this context may play oral agents, when regular visits in clinic and intravenous injection are not needed. The efficacy of oral vinorelbine is well explored, unfortunately the standard dosage regimen сan have quite high especially hematologic toxicity. The metronomic dosing regimen is believed to be as effective as the standard, but is less toxic. In addition, the anti-angiogenic properties of the metronomic mode are described. Taking into account the increasing use of combination of endocrine therapy with CDK4/6 inhibitors in first treatment lines, it is extremely important to study the efficacy and tolerability of various regimens and drugs after progression on combined endocrine therapy. In this article, we represent a clinical case of the use of oral vinorelbine in the metronomic mode in the patient after progression on combination of fulvestrant and palbociclib. Long-term disease control with satisfactory quality of life has been demonstrated.
- 7 August 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 148-153-153
Open AccessClinical case of the use of oral metronomic vinorelbin in patient with metastatic Her2 negative breast cancer
Endocrine therapy in combination with inhibitors of cyclin-dependent kinases 4/6 in first lines is the current standard of treatment of metastatic ER positive Her2 negative breast cancer. After progression on several lines of endocrine therapy according to current principles we apply sequential lines of monochemotherapy. If possible non-toxic agents are prefered in order to maintain high quality of life. The special role in this context may play oral agents, when regular visits in clinic and intravenous injection are not needed. The efficacy of oral vinorelbine is well explored, unfortunately the standard dosage regimen сan have quite high especially hematologic toxicity. The metronomic dosing regimen is believed to be as effective as the standard, but is less toxic. In addition, the anti-angiogenic properties of the metronomic mode are described. Taking into account the increasing use of combination of endocrine therapy with CDK4/6 inhibitors in first treatment lines, it is extremely important to study the efficacy and tolerability of various regimens and drugs after progression on combined endocrine therapy. In this article, we represent a clinical case of the use of oral vinorelbine in the metronomic mode in the patient after progression on combination of fulvestrant and palbociclib. Long-term disease control with satisfactory quality of life has been demonstrated.